Market Intelligence, Clinical Progress, and High-Purity Reagents for B-Cell Malignancy & Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BTK (Bruton's Tyrosine Kinase) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BTK Recombinant Protein (WT & Mutants: C481S, T474I, L528W). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Active kinase. | View BTK Products |
| Gene Delivery | BTK Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. Resistance mutation models. | View BTK Products |
| Benchmark Ab | Anti-BTK (Ibrutinib Competition Epitope). Recombinant positive control for binding assays. | View BTK Products |
| Validator | BTK siRNA Set. For knockdown verification and specificity controls. | View BTK Products |
| Related Target (Selectivity) | ITK (Tec Family). Critical for off-target screening (T-cell toxicity). | View ITK Products |
| Related Target (Pathway) | SYK (Upstream Kinase). Syk-BTK axis validation for combination studies. | View SYK Products |
| Related Target (Parallel) | PIK3CD (PI3Kδ). BCR pathway alternative for combination therapy screening. | View PIK3CD Products |
| Related Target (Resistance Bypass) | PLCG2. Downstream pathway target for resistance bypass screening. | View PLCG2 Products |
| Related Target (Homolog) | TEC. Homolog target for selectivity and off-target safety validation. | View TEC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Covalent Inhibitor Resistance (C481S, T474I mutations) | Sequence-Verified WT & C481S/T474I/L528W Mutant Proteins (>95% purity, Mass Spec confirmed) for resistance profiling |
| Tec Family Selectivity (ITK, BMX, TXK) | Ortholog panel proteins strictly verified by mass spec; Human/Mouse/Cyno available |
| PROTAC Ternary Complex Formation | Full-length BTK Protein (HEK293 expressed) preserving native folding for E3 ligase interaction; optimized for SPR and TR-FRET assay stability |
| Lack of Specificity Controls | Validated BTK siRNA included for target engagement verification |
| Kinase Subfamily Counter Screening | Homolog panel proteins (TEC, ITK, BMX, EGFR) strictly verified by mass spec and theoretical MW |
Live BTK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BTK (ATK) therapeutics is intensifying, with major players shifting focus from first-generation covalent inhibitors to next-generation non-covalent and PROTAC modalities. As resistance mutations (particularly C481S) emerge as the primary clinical challenge, the next wave of R&D is targeting mutation-agnostic binding and CNS penetration for multiple sclerosis and autoimmune indications. First-generation therapies like ibrutinib have saturated the B-cell malignancy market, driving expansion into chronic autoimmune indications such as Multiple Sclerosis (MS) and Systemic Lupus Erythematosus (SLE). This requires exquisitely selective molecules capable of central nervous system (CNS) penetration and minimal off-target kinase activity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Covalent Inhibitors | AbbVie, AstraZeneca, BeiGene | CLL, MCL | C481 Site Integrity Assay (Need C481S mutant protein for resistance screening) |
| Non-covalent (Reversible) | Eli Lilly (Loxo), Merck | Relapsed/Refractory CLL, Ibrutinib-Resistant | Selectivity Assay (Need High-Purity Mutant vs WT Proteins) |
| PROTAC / Degrader | Nurix, Kymera Therapeutics | B-Cell Malignancies (Double Mutant) | Ternary Complex Formation (Need stable, aggregation-free Recombinant Proteins) |
| Small Molecule (CNS-Penetrant) | Sanofi, Novartis | Multiple Sclerosis, SLE | Off-Target Screening (Need TEC/ITK/EGFR Homolog Panels) |
| Combination Therapies | AbbVie, BeiGene | Refractory Lymphoma | Pathway Validation (Need PLCG2, BCL2 Reagents) |
Key Mutations & Functional Domains
BTK (UniProt Q06187) contains PH, SH3, and SH2 domains. Key mutations associated with X-linked agammaglobulinemia (XLA) include:
- C481S (dbSNP:rs1603020228) – confers resistance to covalent inhibitors.
- T474I – another resistance mutation.
- L528W – kinase-dead mutation emerging with non-covalent inhibitors.
Related Targets for Cross-Sell
- View PLCG2 Products: Downstream effector; gain-of-function mutations co-occur with BTK C481S in resistant patients.
- View SYK Products: Upstream kinase; dual SYK/BTK inhibition is a growing trend in autoimmune disease.
- View BCL2 Products: Combination partner; BTKi + BCL2i (e.g., Venetoclax) is reshaping first-line CLL therapy.
- View ITK Products: Tec family member; critical for off-target T-cell toxicity screening.
- View PIK3CD Products: PI3Kδ; alternative BCR pathway target for combination therapy.
- View TEC Products: Homolog; selectivity validation.